All STI clinics to offer VCT to all attendees on their first screening for STIs, and subsequently according to risk2 | | 2002 | Percentage MSM attending STI clinics accepting VCT | | UAPMP | E, W & NI | 47% 2956/6294 | 48% 2903/6021 | 50% 2913/5781 | 57% 3926/6870 | 62% 4637/7431 | 64% 4920/7697 | NA |
| 2002 | Percentage heterosexuals attending STI clinic accepting VCT | | UAPMP | E,W & NI | 26% 16684/62295 | 27% 16023/59591 | 31% 18628/610522 | 39% 27050/69842 | 54% 41125/75638 | 55% 44312/80435 | NA |
| | | | | | | | | | | | | |
To reduce the proportion of individuals newly diagnosed with HIV who have a “late diagnosis” | | NA | Percentage of MSM newly HIV diagnosed with CD4 count below 200 cells ×106/l | | CD4 surveillance | England & Wales | 30% 219/738 | 29% 225/779 | 27% 239/890 | 24% 254/1073 | 25% 255/1010 | 21% 196/948 | NA |
| NA | Percentage of heterosexuals newly diagnosed with a CD4 count below 200 cells ×106/l | | CD4 surveillance | England & Wales | 45% 206/459 | 46% 284/622 | 44% 399/913 | 42% 578/1390 | 44% 674/1538 | 40% 584/1459 | NA |
| | | | | | | | | | | | | |
The universal offer and recommendation of an HIV test as a routine part of antenatal care7 | | 1999 | Percentage HIV infected women diagnosed before delivery | | UAPMP and NSHPC | England | 40% 113/284 | 59% 192/327 | 71% 281/398 | 84% 420/501 | 82% 536/650 | 88% 697/790 | NA |
| 1999 | Percentage exposed infants becoming HIV infected | | UAPMP and NSHPC | England | 17% 48/284 | 12% 40/327 | 9% 37/398 | 6% 31/501 | 7% 43/650 | 5% 39/790 | NA |
| | | | | | | | | | | | | |
To monitor the proportion of HIV infected individuals on triple ARV or more | | NA | Percentage of diagnosed HIV infected MSM on triple ARV therapy or more | | SOPHID | E, W & NI | 56% 5231/9367 | 66% 6656/10156 | 66% 7144/10885 | 64% 8011/12472 | 67% 9062/13593 | 65.2% 9991/15333 | NA |
| | Percentage of diagnosed HIV infected heterosexuals on triple ARV therapy or more | | SOPHID | E,W & NI | 50% 2158/4286 | 63% 3251/5182 | 65% 4094/6296 | 63% 5695/9046 | 64% 7631/12024 | 63.3% 9950/15717 | NA |
| | | | | | | | | | | | | |
To offer all MSM hepatitis B vaccination at their first STI clinic attendance2 | | 2003 | Percentage MSM taking up first dose at their first STI clinic attendance | | HepB3 survey | England | NA | NA | NA | NA | NA | 85% 5598/6553 | NA |
| 2003 | Percentage MSM taking up third dose | | HepB3 survey | England | NA | NA | NA | NA | NA | 39% 5598/6553 | NA |
| | | | | | | | | | | | | |
To reduce waiting times at STI clinics | | 2004 | Percentage patients with emergency appoints seen within 48 hours | | STI waiting times survey | England | NA | NA | NA | NA | NA | NA | 74% 1359/1843 |
| 2004 | Percentage patients with routine appoints seen within 48 hours | | STI waiting times survey | England | NA | NA | NA | NA | NA | NA | 20% 3044/15520 |
| 2004 | Percentage patients with walk-in appoints seen within 48 hours | | STI waiting times survey | England | NA | NA | NA | NA | NA | NA | 79% 4960/6307 |
| | | | | | | | | | | | | |
To control genital chlamydial infection through early detection and treatment of asymptomatic infection among individuals aged under 2517,18 | | 2004 | Chlamydia prevalence among women aged under 25 | | NCSP | England | NA | NA | NA | NA | NA | NA | 10.1% 1538/15241 |
| 2004 | Chlamydia prevalence among men aged under 25 | | NCSP | England | NA | NA | NA | NA | NA | NA | 13.3% 156/1172 |
| | | | | | | | | | | | | |
To reduce the proportion of injecting drug users who share injecting equipment | | NA | Percentage current injectors who report sharing needles/syringes | | UAPMP | E,W & NI | 32% 678/2138 | 33% 748/2276 | 31% 672/2184 | 33% 643/1934 | 34% 601/1775 | 29% 494/1677 | NA |
| NA | Percentage current injectors who report sharing other injecting equipment | | UAPMP | E,W & NI | 54% 1213/2252 | 54% 1297/2418 | 52% 1191/2298 | 51% 1029/2005 | 52% 947/1832 | 50% 830/1670 | NA |